STAT+: PepGen says early trial for muscular dystrophy drug looks promising
The biotech PepGen said Tuesday that its experimental drug had shown, by one key measure, the most promising early data yet in the race to treat a muscle disorder that affects over 100,000 people in the U.S. and Europe. PepGen is a latecomer to the…
ImpactNotable
Published4 h ago (Tue, 10 Nov 2026 12:05:00 GMT)
AuthorJason Mast
MoreLess
Impact score33/100
RatingProbability of 66%.
RegionsGlobal
Retrievedvia rss
ClassifiedTue, 10 Nov 2026 13:01:49 GMT by classifier